Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Red Light Holland’s (TRIP) partner has received Health Canada Approval to supply psilocybin for a new special access program
  • CCrest Laboratories has been working with Shaman Pharma to evaluate the potency of Red Light Holland’s psilocybin truffles
  • Now, this new special access program will allow patients with conditions not treatable by other medications to get access to psilocybin
  • Red Light Holland is an Ontario-based corporation engaged in the production, growth, and sale of a premium brand of magic truffles
  • Shares in Red Light Holland Corp. (TRIP) are up 7.41 per cent, trading at $0.145 per share

Red Light Holland’s (TRIP) partner has received Health Canada Approval to supply psilocybin for a new special access program.

CCrest Laboratories has been working with Shaman Pharma to evaluate the potency of Red Light Holland’s psilocybin truffles under a Health Canada Controlled Drugs & Substances license. Red Light Holland has received two reports so far, once in November and again in January.

Now, this new special access program will allow patients with conditions not treatable by other medications to get access to psilocybin.

“As a company we want to make a positive difference in this world,” said Red Light Holland CEO Todd Shapiro, “which is why we’d like to offer our lab tested truffles via CCrest Labs, free of charge, to patients who are granted special access in Canada.”

Red Light Holland hopes to continue to provide CCrest Laboratories with a source of their naturally occurring psilocybin truffles, which would then be made available free of charge for patients who are eligible under the special access program based on compassionate need.

“CCrest Labs and Red Light Holland are aiming to continue to work with the Canadian Government to ensure the success of this program,” remarked Alex Grenier, CEO of Shaman Pharma and President of CCrest Laboratories.

“We’d like to thank Health Canada as well,” said Mr. Grenier, “for their progressive views and continued support for allowing us to get two psilocybin import licences to ship Red Light Holland products over international borders and for approving us to supply psilocybin to the new special access program.”

Red Light Holland is an Ontario-based corporation engaged in the production, growth, and sale of a premium brand of magic truffles.

Shares in Red Light Holland Corp. (TRIP) are up 7.41 per cent, trading at $0.145 per share as of 11:04 am EST.

More From The Market Herald

" Optimi Health (CSE:OPTI) signs psilocybin supply agreement with Halucenex Life Sciences

Optimi Health (OPTI) has announced a supply agreement with Halucenex Life Sciences Inc., a wholly-owned subsidiary of Creso Pharma of Australia.

" Revive (CSE:RVV) gets FDA OK for Bucillamine trials to treat COVID-19

Revive Therapeutics (RVV), a cannabis and psychedelic healthcare company has received feedback from the U.S. FDA to help advance Bucillamine.

" Clearmind Medicine (CSE:MIND) and SciSparc report positive results for Psychedelic Combination Treatment

Clearmind Medicine (MND) has released favourable safety profile results from its joint pre-clinical trial with SciSparc Ltd. (NASDAQ: SPRC).

" Optimi Health (CSE:OPTI) acquires catalog of psychedelic and functional mushroom genetics

Optimi Health (OPTI) has acquired a catalog of psilocybin and functional mushroom strains.